Sarepta Therapeutics, Inc. (SRPT) Shares Sold by Morgan Stanley

Lester Mason
January 13, 2018

Benchmark Capital Advisors bought 10,400 shares as the company's stock rose 22.49% with the market. The fund owned 483,547 shares of the company's stock after selling 484,180 shares during the period. The stock increased 0.23% or $0.28 during the last trading session, reaching $123.43. About 637,036 shares traded. MCBC Holdings, Inc. (NASDAQ:MCFT) has risen 116.60% since January 12, 2017 and is uptrending. It has underperformed by 18.88% the S&P500.

Sarepta Therapeutics, Inc. has a 12 month low of $8.00 and a 12 month high of $63.73. Citigroup reported 43,251 shares. The institutional investor held 200,000 shares of the health care company at the end of 2017Q3, valued at $9.07M, up from 100,000 at the end of the previous reported quarter. The institutional investor held 4,474 shares of the consumer services company at the end of 2017Q3, valued at $4.30M, up from 3,947 at the end of the previous reported quarter. Its last month's stock price volatility remained 5.33% which for the week approaches 4.18%.

In other Sarepta Therapeutics news, SVP Shamim Ruff sold 10,000 shares of the company's stock in a transaction dated Monday, November 6th.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) closed down -0.15 points or -0.25% at $58.99 with 1.63 mln shares exchanging hands. It has outperformed by 80.12% the S&P500.

Artal Group Sa, which manages about $5.81B US Long portfolio, decreased its stake in Bristol Myers Squibb Co (Call) (NYSE:BMY) by 350,000 shares to 650,000 shares, valued at $41.43 million in 2017Q3, according to the filing.

Investors sentiment decreased to 0.89 in 2017 Q3.

Since October 3, 2017, it had 0 insider buys, and 1 sale for $575,000 activity. The number of shares now owned by investors are 164.79 mln. 127 funds opened positions while 657 raised stakes. (NYSE:MSI). Caxton Associate LP invested 0.01% in Motorola Solutions, Inc. Following the completion of the sale, the director now owns 13,333 shares in the company, valued at approximately $745,181.37. 133.54 million shares or 0.41% less from 134.09 million shares in 2017Q2 were reported. Virginia-based Virginia Retirement Et Al has invested 0.05% in The J.M. Smucker Company (NYSE:SJM). (NASDAQ:AMZN). Kidder Stephen W owns 375 shares. Winslow Evans And Crocker holds 1,000 shares or 0.02% of its portfolio. Kazazian Asset Management Limited reported 5,832 shares. Great West Life Assurance Can reported 219,136 shares. 46,164 were reported by Motley Fool Wealth Management Limited Co. Atwood Palmer has 13 shares.


Among 16 analysts covering Motorola Solutions (NYSE:MSI), 11 have Buy rating, 1 Sell and 4 Hold. Therefore 32% are positive. Sarepta Therapeutics had 95 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has "Overweight" rating by Piper Jaffray given on Monday, August 24. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company's stock valued at $68,495,000 after buying an additional 481,890 shares during the period. The firm earned "Outperform" rating on Friday, July 24 by RBC Capital Markets. The rating was upgraded by William Blair to "Outperform" on Monday, September 19. Argus Research has "Buy" rating and $84 target. (NASDAQ:SRPT) on Wednesday, September 28 with "Outperform" rating. Deutsche Bank initiated the shares of SJM in report on Wednesday, February 15 with "Hold" rating. Needham maintained it with "Buy" rating and $75.0 target in Thursday, October 26 report. On Wednesday, August 26 the stock rating was maintained by Cowen & Co with "Hold". Susquehanna maintained the stock with "Hold" rating in Wednesday, August 23 report. SunTrust downgraded Sarepta Therapeutics, Inc. The last close places the company's stock about $2.52 off its 52 week high of $3.22 and $0.03 above the 52 week low of $0.67. SJM's profit will be $243.09M for 14.42 P/E if the $2.14 EPS becomes a reality. Jennison Ltd Liability Corporation reported 0.05% of its portfolio in Sarepta Therapeutics, Inc.

Sphera Funds Management Ltd, which manages about $700.90 million US Long portfolio, upped its stake in Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 105,000 shares to 145,000 shares, valued at $7.83 million in 2017Q3, according to the filing. Morgan Stanley maintained Sarepta Therapeutics, Inc.

Investors sentiment increased to 2.88 in 2017 Q3. Its up 1.36, from 1.52 in 2017Q2.

Want to see what other hedge funds are holding SRPT? (NYSE:MSI). Brinker holds 9,466 shares. Cowen & Co maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT). 6,792 were accumulated by Bnp Paribas Arbitrage Sa. Pinnacle stated it has 0.28% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 142,900 shares. New York-based Rothschild Asset Mgmt has invested 0.31% in Nektar Therapeutics (NASDAQ:NKTR).

Shares of Sarepta Therapeutics (SRPT) traded down $0.15 during mid-day trading on Friday, reaching $58.99. First Advsrs L P holds 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 500 shares. 12,722 were accumulated by Dupont Cap. Neuberger Berman Group LLC bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth about $1,134,000. (NASDAQ:SRPT) for 2,471 shares. Gotham Asset Ltd Liability Co has 0.01% invested in Sarepta Therapeutics, Inc.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, October 25th. (NASDAQ:AMZN) for 858 shares. Rock Springs Mgmt Limited Partnership holds 0.54% or 259,200 shares in its portfolio. The stock of Sarepta Therapeutics, Inc. (NASDAQ:MCFT) has "Sector Weight" rating given on Thursday, August 31 by KeyBanc Capital Markets. They expect $-0.35 EPS, up 77.85% or $1.23 from last year's $-1.58 per share. During the same quarter in the prior year, the firm posted ($0.95) earnings per share. sell-side analysts predict that Sarepta Therapeutics will post -3.07 EPS for the current fiscal year.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER